St. Louis, Missouri, March 7, 2016 – The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, today announced the introduction of seven Certified Spiking Solutions® of antiviral and antiretroviral drugs to its line of Certified Reference Materials (CRMs) used in testing laboratories around the world.
Antiviral and antiretroviral drug therapy is a mainstay in the treatment of human immunodeficiency virus (HIV) infection.1 In HIV treatment, therapeutic drug monitoring (TDM) of antiretroviral is often considered to achieve optimal drug concentrations for viral suppression, to monitor adherence, and to minimize drug-associated toxicity.2,3 TDM is also useful in HIV patient populations administered CYP450 interacting agents.3
The new Cerilliant® product line includes solution-based CRMs of acyclovir, ganciclovir, efavirenz, nevirapine, lamivudine, zidovudine and ritonavir.
Cerilliant®-certified reference solutions are manufactured using a validated process that ensures the highest level of accuracy for critical quantitative mass spectrometry-based applications from TDM, diagnostic testing, endocrinology and pharmaceutical research to toxicology, forensic testing and clinical chemistry. MilliporeSigma offers a comprehensive listing of parent drug, metabolite and internal standard Certified Spiking Solutions® for clinical diagnostic testing applications, including immunosuppressants, bile acids, vitamins including 25-hydroxyvitamin D, steroids and hormones, catecholamines, cardiac drugs, antidepressants and pain management drugs.
Cerilliant and Certified Spiking Solutions are registered trademarks of Sigma-Aldrich Corp., which was acquired by Merck KGaA, Darmstadt, Germany last year. The name of the merged companies is MilliporeSigma in the U.S. and Canada and Merck elsewhere.